FDA caution hurts GSK’s Advair drug
‘The Food and Drug Administration has urged physicians to restrict the use of Advair and recommended stronger warnings be added to its packaging, saying GlaxoSmithKline’s popular asthma medicine increases the chance of deadly complications from the respiratory disease.
Surprised analysts predict the regulatory proposals would slow Advair sales growth in the short term, which could hurt GSK’s outlook on Wall Street. The disk-shaped, purple-and-white inhaler that dispenses two powerful chemicals is the British drug maker’s best seller. Last year, it generated about $4.5 billion in sales, more than half in the United States.
Several local physicians said there aren’t good alternatives to Advair and that they plan to continue prescribing the treatment.’
Read more at FDA caution hurts GSK’s Advair drug
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax